Get Live Data

Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. REDX.L Share Price
  4. REDX.L Share Regulatory News
  5. Notice of Results

Pin to quick picksREDX.L Regulatory News (REDX)

REDX.L Information
  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

31 Oct 2018 07:00

RNS Number : 7754F
Redx Pharma plc
31 October 2018
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Notice of Results

 

Alderley Park, 31 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, will announce its preliminary results for the year ended 30 September 2018 on Monday 19 November 2018.

 

For further information, please contact:

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Advisor & Broker)

 T: +44 20 7894 7000

Phil Davies

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

 

About Redx Pharma Plc 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORFKKDDOBDDOKN
12345678910
Date   Source Headline
20th Mar 202310:38 amRNSForm 8.5 (EPT/RI)
16th Mar 20239:48 amRNSForm 8.5 (EPT/RI)
15th Mar 20234:40 pmRNSSecond Price Monitoring Extn
15th Mar 20234:35 pmRNSPrice Monitoring Extension
15th Mar 20232:05 pmRNSSecond Price Monitoring Extn
15th Mar 20232:00 pmRNSPrice Monitoring Extension
15th Mar 202310:50 amRNSStatement re: Jounce Therapeutics Press Release
14th Mar 202311:45 amRNSResult of Annual General Meeting
10th Mar 20237:00 amRNSForm 8.3 - Redx Pharma Plc
9th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20232:00 pmBUSForm 8.3 - REDX PHARMA PLC
9th Mar 202311:22 amRNSForm 8 (OPD) - Jounce Therapeutics, Inc
9th Mar 202311:15 amRNSForm 8 (OPD) - Redx Pharma Plc
9th Mar 20238:34 amRNSForm 8.5 (EPT/RI)
9th Mar 20237:00 amRNSForm 8.3 - Redx Pharma plc
8th Mar 20239:05 amRNSSecond Price Monitoring Extn
8th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20238:38 amRNSForm 8.5 (EPT/RI)
8th Mar 20238:16 amRNSForm 8 (OPD) Jounce Therapeutics, Inc.
8th Mar 20237:00 amRNSRXC004 Topline Data From a Phase 2 Module
7th Mar 20238:30 amRNSForm 8.5 (EPT/RI)
3rd Mar 20233:08 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
2nd Mar 20238:09 amRNSForm 8.5 (EPT/RI)
1st Mar 20238:48 amRNSForm 8.5 (EPT/RI)
1st Mar 20237:00 amRNSRedx to Present at Cowen Health Care Conference
28th Feb 20236:03 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
27th Feb 20234:58 pmRNSForm 8.3 - Jounce Therapeutics, Inc
27th Feb 20234:47 pmRNSForm 8.3 - Redx Pharma plc
27th Feb 20234:36 pmRNSForm 8.3 - Jounce Therapeutics, Inc
27th Feb 20232:40 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
27th Feb 20238:48 amRNSForm 8.5 (EPT/RI)
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
24th Feb 20233:13 pmRNSReplacement Form 8.3 - Jounce Therapeutics, Inc.
24th Feb 20232:02 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
24th Feb 202310:18 amRNSForm 8.5 (EPT/RI)
24th Feb 20237:00 amRNSForm 8.3 - Redx Pharma plc
23rd Feb 20237:15 amRNSRecommended Business Combination
23rd Feb 20237:01 amRNSRecommended Business Combination
15th Feb 20234:38 pmRNSNotice of AGM
9th Feb 20237:00 amRNSProgress Update on RXC007 Clinical Programme
23rd Jan 20237:00 amRNSRedx to Present at Wnt & ß-Catenin Pathway Summit
21st Dec 20227:00 amRNSNew Grant of Options
20th Dec 20227:00 amRNSFinal Results for the Year Ended 30 September 2022
16th Dec 20227:00 amRNSClinical Trial Agreement with MSD
13th Dec 20227:00 amRNSNotice of Preliminary Results
17th Nov 20227:00 amRNSRedx to Present Poster at IBD Nordic Conference
10th Nov 20222:00 pmRNSRXC004 Phase 2 Combination Arms to Open Enrolment
10th Nov 20227:00 amRNSRedx to Present at Jefferies London
7th Nov 20227:00 amRNSRedx Presenting at AFDD meeting
3rd Nov 20227:00 amRNSRedx to Present RXC004 Phase 1 Combination Data
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.